Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd.

复星安特金(成都)生物制药股份有限公司

Develops, manufactures and commercializes prophylactic vaccines in China, including rabies and influenza vaccines, with a pipeline targeting pneumococcal and meningococcal diseases; operates R&D and manufacturing bases in Chengdu and Dalian, and ranked third in 2023 (per prospectus).

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Single product, business line or region
• Government or SOE customers and tenders
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Business changes and acquisitions
• Capacity and utilisation
• Seasonality and cyclicality
• Losses and path to profitability
• Net current liabilities or net liabilities
• Negative operating cash flow
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Adverse change after the track record
• Non-recurring gains and losses
• Related-party transactions and balances
• Chapter 18A biotech